Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.60 USD
Change Today -0.15 / -5.45%
Volume 1.2M
OREX On Other Exchanges
Symbol
Exchange
Stuttgart
As of 3:09 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Peter K. Honig M.D., MPH

Director and Chairperson of Research & Development Strategy Committee,Orexigen Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 16 board members in 2 different organizations across 2 different industries.

See Board Relationships
58$306,206

Background*

Dr. Peter K. Honig, MD, MPH, serves as the Head of Global Regulatory Affairs at AstraZeneca, Inc. Dr. Honig served as a Senior Vice President of Worldwide Regulatory Affairs and Product Safety at Merck & Company. He has over 20 years of clinical and regulatory policy experience from past roles with Merck & Company and the U.S. Food and Drug Administration (FDA). He served as Merck's Vice President, Worldwide Product Safety and Quality Assurance. He originally joined ...

Read Full Background

Corporate Headquarters*

3344 North Torrey Pines Court
La Jolla, California 92037

United States

Phone: 858-875-8600
Fax: 858-875-8650

Board Members Memberships*

2010-Present
Director and Chairperson of Research & Development Strategy Committee
2014-Present
Non-Employee Director and Member of Nominating & Corporate Governance Committee

Education*

BA
Columbia University
MD
Edward S. Harkness Eye Institute
MPH
Mailman School of Public Health, Columbia University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$65,646
Total Calculated Compensation$306,206
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $2.60 USD -0.15

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jack Lief Ph.D.Co-Founder, Chairman, Chief Executive Officer, President and Principal Financial Officer
Arena Pharmaceuticals, Inc.
$746.8K
Seth H. Z. Fischer Chief Executive Officer, Chief Commercial Officer and Director
VIVUS Inc.
$650.0K
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
2.0M GBP
Lars Rebien Sørensen Chief Executive Officer, President and Member of Executive Management
Novo Nordisk A/S
kr15.2M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.